JBJürgen Brockmöller

Jürgen Brockmöller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jürgen Brockmöller has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comprehensive characterization of the OCT1 phenylalanine-244-alanine substitution reveals highly substrate-dependent effects on transporter function

    by Carla Isabel Wittern, Sophie Schröder, Ole Jensen, Jürgen Brockmöller, Lukas Gebauer


  • Open Access

    Oral Drug Absorption and Drug Disposition in Critically Ill Cardiac Patients

    by Lars-Olav Harnisch, Jürgen Brockmöller, Anne Hapke, Juliane Sindern, Ellen Bruns, Ruben Evertz, Karl Toischer, Bernhard C. Danner, Dorothee Mielke, Veit Rohde, et al.

    (1) Background: In critically ill cardiac patients, parenteral and enteral food and drug administration routes may be used. However, it is not well known how drug absorption and metabolism are altered in this group of adult patients. Here, we analyze drug absorption and metabolism in patients after cardiogenic shock using the pharmacokinetics of therapeutically indicated esomeprazole. (2) Methods: The pharmacokinetics of esomeprazole were analyzed in a consecutive series of patients with cardiogenic shock and controls before and after elective cardiac surgery. Esomeprazole was administered orally or with a nasogastric tube and once as an intravenous infusion. (3) Results: The maximum plasma concentration and AUC of esomeprazole were, on average, only half in critically ill patients compared with controls (p < 0.005) and remained lower even seven days later. Interestingly, esomeprazole absorption was also markedly compromised on day 1 after elective surgery. The metabolites of esomeprazole showed a high variability between patients. The esomeprazole sulfone/esomeprazole ratio reflecting CYP3A4 activity was significantly lower in critically ill patients even up to day 7, and this ratio was negatively correlated with CRP values (p = 0.002). The 5′-OH-esomeprazole and 5-O-desmethyl-esomeprazol ratios reflecting CYP2C19 activity did not differ significantly between critically ill and control patients. (4) Conclusions: Gastrointestinal drug absorption can be significantly reduced in critically ill cardiac patients compared with elective patients with stable cardiovascular disease. The decrease in bioavailability indicates that, under these conditions, any vital medication should be administered intravenously to maintain high levels of medications. After shock, hepatic metabolism via the CYP3A4 enzyme may be reduced.


  • Open Access

    Amino acids in transmembrane helix 1 confer major functional differences between human and mouse orthologs of the polyspecific membrane transporter OCT1

    by Marleen J. Meyer, Pascale C.F. Schreier, Mert Basaran, Stefaniia Vlasova, Tina Seitz, Jürgen Brockmöller, Barbara Zdrazil, Mladen V. Tzvetkov


  • Top Cited Papers
    Open Access

    Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study

    by Ekkehard Schütz, Anna Fischer, Julia Beck, Markus Harden, Martina Koch, Tilo Wuensch, Martin Stockmann, Björn Nashan, Otto Kollmar, Johannes Matthaei, et al.

    Graft-derived cell-free DNA (GcfDNA), which is released into the blood stream by necrotic and apoptotic cells, is a promising noninvasive organ integrity biomarker. In liver transplantation (LTx), neither conventional liver function tests (LTFs) nor immunosuppressive drug monitoring are very effective for rejection monitoring. We therefore hypothesized that the quantitative measurement of donor-derived cell-free DNA (cfDNA) would have independent value for the assessment of graft integrity, including damage from acute rejection. Traditional LFTs were performed and plasma GcfDNA was monitored in 115 adults post-LTx at three German transplant centers as part of a prospective, observational, multicenter cohort trial. GcfDNA percentage (graft cfDNA/total cfDNA) was measured using droplet digital PCR (ddPCR), based on a limited number of predefined single nucleotide polymorphisms, enabling same-day turn-around. The same method was used to quantify blood microchimerism. GcfDNA was increased >50% on day 1 post-LTx, presumably from ischemia/reperfusion damage, but rapidly declined in patients without graft injury within 7 to 10 d to a median p < 0.001). Only slightly higher values (median 5.9%, 95% CI 4.4%–10.3%) were found in 68 samples from 17 hepatitis C virus (HCV)–positive, rejection-free patients. LFTs had low overall correlations (r = 0.28–0.62) with GcfDNA and showed greater overlap between patient subgroups, especially between acute rejection and HCV+ patients. Multivariable logistic regression modeling demonstrated that GcfDNA provided additional LFT-independent information on graft integrity. Diagnostic sensitivity and specificity were 90.3% (95% CI 74.2%–98.0%) and 92.9% (95% CI 89.3%–95.6%), respectively, for GcfDNA at a threshold value of 10%. The area under the receiver operator characteristic curve was higher for GcfDNA (97.1%, 95% CI 93.4%–100%) than for same-day conventional LFTs (AST: 95.7%; ALT: 95.2%; γ-GT: 94.5%; bilirubin: 82.6%). An evaluation of microchimerism revealed that the maximum donor DNA in circulating white blood cells was only 0.068%. GcfDNA percentage can be influenced by major changes in host cfDNA (e.g., due to leukopenia or leukocytosis). One limitation of our study is that exact time-matched GcfDNA and LFT samples were not available for all patient visits. In this study, determination of GcfDNA in plasma by ddPCR allowed for earlier and more sensitive discrimination of acute rejection in LTx patients as compared with conventional LFTs. Potential blood microchimerism was quantitatively low and had no significant influence on GcfDNA value. Further research, which should ideally include protocol biopsies, will be needed to establish the practical value of GcfDNA measurements in the management of LTx patients.


  • Routine Micromethod for the Determination of Vitamin K1 in Human Plasma

    by Ingolf Meineke, Cornelia Willnow, Julia Stingl, Jürgen Brockmöller

    A selective and sensitive high-performance liquid chromatographic method with fluorescence detection after postcolumn reduction is described for the routine measurement of vitamin K1 in plasma samples of 100 µL of volume. Liquid-liquid extraction was used for the sample preparation with vitamin K2 as an internal standard. For the chromatographic separation, a standard C18 column was applied. The calibration range used was from 2 to 500 ng/mL. At the low level (5 ng/mL), a coefficient of variation of 14.9% was observed interday in the quality control samples, whereas at the intermediate (50 ng/mL) and high (200 ng/mL) levels such of 6.8% and 8.7% were found. The method has proven robust and convenient for the analysis of samples from clinical pharmacological studies.


  • Bioinformatic and functional analysis of TGFBR1 polymorphisms

    by Markus A. Schirmer, Arne O. Hoffmann, Radu Campean, Jörg H. Janke, Laura M. Zidek, Marion Hoffmann, Moritz Kruse, Daniel Sehrt, Mladen V. Tzvetkov, Margret Rave-Fränk, et al.

    The transforming growth factor-beta (TGFB) pathway has substantial impact on cellular functions, cell proliferation, and apoptosis. We used bioinformatics, gene expression, and cell biological assays to evaluate the functionality of frequent inherited germline polymorphisms in the TGFB receptor 1 (TGFBR1). In an exploratory (n=55) and confirmatory (n=106) study, we analyzed the TGFB1 pathway after incubation with TGFbeta1 ligand and after exposure to X-rays in peripheral blood human mononuclear cells. Expression of TGFB pathway genes was assessed by real-time PCR, and cellular viability was analyzed by flow cytometry. A total of six polymorphisms including the deletion variant (*6A) were identified to tag currently known common genetic variations in TGFBR1 and were analyzed in relation to the phenotypes. In accordance with a negative feedback mechanism, incubations with the ligand TGFbeta1 was followed by up-regulation of the intracellular SMAD7 and down-regulation of the SMAD3 mRNA molecules. The TGFBR1*6A deletion variant attenuated the suppression of SMAD3 in response to TGFbeta1 (P=0.02, in both studies). Moreover, cells harboring *6A were more sensitive toward cytotoxic effects of irradiation (P=0.001 after adjustment for age and sex). Cells were particularly prone toward radiation toxicity when carrying, in addition to *6A, the variant allele of rs11568785, which exhibits a strong genetic selection signature. The *6A deletion and the linked rs11568785 polymorphisms seem to attenuate TGFB signaling. This should be considered not only for clinical-epidemiological studies on cancer susceptibility but may also be relevant for side effects from drugs or radiotherapy.


  • Pharmakogenetische Tests in der zukünftigen medizinischen Versorgung: Implikationen für Patienten und Ärzte

    by A. Rogausch, J. Brockmöller, W. Himmel

    Ziel: Die Art der Einbindung pharmakogenetischer Untersuchungen in den medizinischen Alltag wird maßgeblich davon beeinflusst werden, ob und unter welchen Rahmenbedingungen Patienten und Ärzte diese akzeptieren. Ein Literatur-Review sollte die Frage beantworten, welche Implikationen und Konsequenzen Patienten und Ärzte bzw. Wissenschaftler bei der Anwendung pharmakogenetischer Untersuchungen erwarten oder vermuten. Methodik: Umfassende Literaturrecherche in MEDLINE (Stichworte: Pharmacogenetics, Delivery of Health Care, Ethics, Attitude, Patient Acceptance of Health Care) nach empirischen und theoretischen Arbeiten, die psychische, familiäre, soziale und ethische Implikationen pharmakogenetischer Untersuchungen beschreiben, um relevante Themen als Grundlage weiterer empirischer Arbeiten zu extrahieren. Ergebnisse und Schlussfolgerungen: Neben antizipierten Vorteilen könnten folgende Faktoren die Akzeptanz pharmakogenetischer Untersuchungen beeinflussen: Erwartung negativer psychosozialer Konsequenzen sowie Sorge um Diskriminierung oder Nichteinhaltung des Datenschutzes. Zudem dürften die Information über Testergebnisse und die Vermittlung der Implikationen pharmakogenetischer Untersuchungen aufgrund ihrer Komplexität eine Herausforderung in der Arzt-Patienten-Beziehung darstellen. Da sich diese Gesichtspunkte vornehmlich aus theoretisch-konzeptionellen Arbeiten ableiten, sind empirische Untersuchungen zur Einstellung von Patienten und Ärzten sowie zum medizinischen und gesundheitsökonomischen Nutzen pharmakogenetischer Untersuchungen dringend erforderlich. Purpose: Since public acceptance of pharmacogenetic testing will largely influence their implementation in routine medical care, common implications of pharmacogenetic testing from patients’, physicians’ and scientists’ perspective are reviewed. Methods: Broad literature review (MEDLINE; MeSH terms: Pharmacogenetics, Delivery of Health Care, Ethics, Attitude, Patient Acceptance of Health Care) of empirical and theoretical studies describing psychological, family-related, social, and ethical consequences of pharmacogenetic testing to describe relevant aspects for further empirical studies. Results: Apart from anticipated benefit, acceptance of pharmacogenetic testing might be influenced by the following: Expectation of negative psychosocial consequences, fear of discrimination or violation of privacy. Due to its great complexity, understanding of test results and explanation of their impact pose new challenges for physician-patient relations. Since most studies are conceptual, empirical studies exploring attitudes of patients/physicians and determining medical as well as economic value of pharmacogenetic testing are imperative.